Skip to main content
Katherine Tkaczuk, MD, Oncology, Baltimore, MD

KatherineHannaTkaczukMD

Oncology Baltimore, MD

Breast Cancer, Hematologic Oncology

Professor of Medicine, University Maryland School of Medicine; Director, Breast Evaluation and Treatment Program, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

Overview of Dr. Tkaczuk

Dr. Katherine Tkaczuk is an oncologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including University of Maryland Medical Center, University of Maryland Baltimore Washington Medical Center, and Veterans Affairs Maryland Health Care System-Baltimore Division. She received her medical degree from Wroclaw Medical University and has been in practice 33 years. Dr. Tkaczuk accepts several types of health insurance, listed below. She is one of 30 doctors at University of Maryland Baltimore Washington Medical Center and one of 100 doctors at University of Maryland Medical Center who specialize in Oncology. She has more than 80 publications and over 500 citings.

Education & Training

  • University of Maryland
    University of MarylandFellowship, Hematology and Medical Oncology, 1989 - 1992
  • St Agnes HealthCare
    St Agnes HealthCareResidency, Internal Medicine, 1986 - 1989
  • St Agnes HealthCare
    St Agnes HealthCareInternship, Internal Medicine, 1986 - 1987
  • Wroclaw Medical University
    Wroclaw Medical UniversityClass of 1984

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1987 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2009-2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Post-ASCO News Alert: AstraZeneca’s/Merck’s Lynparza Use in Niche HR+ gBRCA-Mutant Breast Cancer Subgroup Could Compete with Verzenio
    Post-ASCO News Alert: AstraZeneca’s/Merck’s Lynparza Use in Niche HR+ gBRCA-Mutant Breast Cancer Subgroup Could Compete with VerzenioJune 21st, 2021
  • Is There Medication to Prevent Breast Cancer?
    Is There Medication to Prevent Breast Cancer?December 1st, 2023

Grant Support

  • Glycoprotein 88 Blood Test as Screening Test for Breast CancerMaryland Industry Partnership Grant2014–Present

Professional Memberships

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    CareFirst BlueChoice Advantage
    CareFirst BlueChoice Network POS
    CareFirst BluePreferred PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Cofinity PPO
    First Health PPO
    Great West PPO
    HealthAmerica HealthAssurance PPO
    Humana ChoiceCare Network PPO
    Medical Mutual of Ohio SuperMed Plus
    Medical Mutual of Ohio SuperMed POS
    Multiplan PHCS PPO
    Multiplan PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment